Literature DB >> 9915733

Questionnaire study and audit of use of angiotensin converting enzyme inhibitor and monitoring in general practice: the need for guidelines to prevent renal failure.

P A Kalra1, M Kumwenda, P MacDowall, M O Roland.   

Abstract

OBJECTIVES: To determine the current pattern of use of angiotensin converting enzyme inhibitor and monitoring of renal function in general practice and to audit all admissions to a regional renal unit for uraemia related to use of these drugs.
DESIGN: Postal questionnaire sent to 400 general practitioners; audit of clinical notes of all patients receiving these drugs in one large general practice; audit of all cases of uraemia (creatinine concentration >500 micromol/l) related to treatment presenting to hospital renal services over 12 months.
SETTING: General practices in the North Wales health authority and one in central Manchester. Regional renal unit in Salford. MAIN OUTCOME MEASURES: Proportion of general practitioners who regularly monitored renal function before and after initiation of angiotensin converting enzyme inhibitors. Indications for treatment and details of monitoring of renal function in patients receiving these drugs. Incidence of related uraemia and evidence of comorbid disease, other aetiological factors, delayed detection, and patient outcome.
RESULTS: 277 (69%) general practitioners replied; 235 (85%) checked renal function before but only 93 (34%) after the start of treatment, and 42 (15%) never checked renal function. Angiotensin converting enzyme inhibitors were prescribed for 162 patients from a total of 3625 aged >35 years (mean age 66.4 (SD 15.9) years). Monitoring of renal function occurred before treatment in 55 (45%) and after start of treatment in 35 (29%) of the 122 patients treated in general practice. Angiotensin converting enzyme inhibitors could be causally implicated in 9 (7%) of 135 admissions for uraemia (mean age 74.2 (7. 2) v 62.1 (2.1) years; P<0.01). 3 patients had renovascular disease and 6 had congestive cardiac failure with another intercurrent illness. Renal function had not been checked in any patient after the start of treatment; mean duration of illness before admission was 10.5 (3.2) days. Mean length of hospital stay was 20.9 (10.4) days; there were 8 survivors.
CONCLUSION: Cases of uraemia related to treatment with angiotensin converting enzyme inhibitors are still encountered and are often detected late because of lack of judicious monitoring of renal function in vulnerable, often elderly, patients, especially at times of intercurrent illness. Guidelines for appropriate monitoring of renal function may help to minimise the problem.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9915733      PMCID: PMC27706          DOI: 10.1136/bmj.318.7178.234

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  10 in total

1.  STENOSIS OF RENAL ARTERY: AN UNSELECTED NECROPSY STUDY.

Authors:  C J SCHWARTZ; T A WHITE
Journal:  Br Med J       Date:  1964-12-05

2.  Unsuspected renal artery stenosis in peripheral vascular disease.

Authors:  A H Choudhri; J G Cleland; P C Rowlands; T L Tran; M McCarty; M A al-Kutoubi
Journal:  BMJ       Date:  1990-11-24

3.  Renovascular disease and renal complications of angiotensin-converting enzyme inhibitor therapy.

Authors:  P A Kalra; H Mamtora; A M Holmes; S Waldek
Journal:  Q J Med       Date:  1990-10

Review 4.  North of England evidence based development project: guideline for angiotensin converting enzyme inhibitors in primary care management of adults with symptomatic heart failure.

Authors:  M Eccles; N Freemantle; J Mason
Journal:  BMJ       Date:  1998-05-02

5.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

Authors:  Salim Yusuf; Bertram Pitt; Clarence E Davis; William B Hood; Jay N Cohn
Journal:  N Engl J Med       Date:  1991-08-01       Impact factor: 91.245

Review 6.  Diagnosis and management of heart failure.

Authors:  H J Dargie; J J McMurray
Journal:  BMJ       Date:  1994-01-29

7.  Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kidney.

Authors:  D E Hricik; P J Browning; R Kopelman; W E Goorno; N E Madias; V J Dzau
Journal:  N Engl J Med       Date:  1983-02-17       Impact factor: 91.245

8.  Renal artery stenosis: prevalence and associated risk factors in patients undergoing routine cardiac catheterization.

Authors:  M B Harding; L R Smith; S I Himmelstein; K Harrison; H R Phillips; S J Schwab; J B Hermiller; C J Davidson; T M Bashore
Journal:  J Am Soc Nephrol       Date:  1992-05       Impact factor: 10.121

9.  Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

Authors:  B Pitt; R Segal; F A Martinez; G Meurers; A J Cowley; I Thomas; P C Deedwania; D E Ney; D B Snavely; P I Chang
Journal:  Lancet       Date:  1997-03-15       Impact factor: 79.321

10.  Risk of morbidity from renovascular disease in elderly patients with congestive cardiac failure.

Authors:  P MacDowall; P A Kalra; D J O'Donoghue; S Waldek; H Mamtora; K Brown
Journal:  Lancet       Date:  1998-07-04       Impact factor: 79.321

  10 in total
  14 in total

1.  Audit of use of ACE inhibitors and monitoring in general practice. Guidelines on monitoring, on their own, are not sufficient.

Authors:  N Freemantle; J Mason; M Eccles
Journal:  BMJ       Date:  1999-06-19

2.  Oversight: a retrospective study of biochemical monitoring in patients beginning antihypertensive drug treatment in primary care.

Authors:  Jamie J Coleman; Sarah E McDowell; Stephen J W Evans; Paramjit S Gill; Robin E Ferner
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

3.  Late referral for assessment of renal failure.

Authors:  Frank Kee; Elizabeth A Reaney; A Peter Maxwell; Damian G Fogarty; Gerard Savage; C Christopher Patterson
Journal:  J Epidemiol Community Health       Date:  2005-05       Impact factor: 3.710

4.  Physicians make different decisions from nephrologists at serum creatinine 2.0 mg/dl.

Authors:  Kaichiro Tamba; Eiji Kusano; Kaoru Tabei; Eiji Kajii; Yasushi Asano
Journal:  Clin Exp Nephrol       Date:  2009-04-22       Impact factor: 2.801

Review 5.  Biochemical monitoring of patients treated with antihypertensive therapy for adverse drug reactions: a systematic review.

Authors:  Sarah E McDowell; Robin E Ferner
Journal:  Drug Saf       Date:  2011-11-01       Impact factor: 5.606

6.  Adherence to renal function monitoring guidelines in patients starting antihypertensive therapy with diuretics and RAAS inhibitors: a retrospective cohort study.

Authors:  Jan C van Blijderveen; Sabine M Straus; Maria A de Ridder; Bruno H Stricker; Miriam C Sturkenboom; Katia M Verhamme
Journal:  Drug Saf       Date:  2014-05       Impact factor: 5.606

7.  Adherence to biochemical monitoring recommendations in patients starting with renin angiotensin system inhibitors: a retrospective cohort study in the Netherlands.

Authors:  Janet E M Bootsma; Margreet F Warlé-van Herwaarden; André L M Verbeek; Peter Füssenich; Peter A G M De Smet; Marcel G Olde Rikkert; Cornelis Kramers
Journal:  Drug Saf       Date:  2011-07-01       Impact factor: 5.606

8.  Standardised monitoring of patients on long-term medication in primary care.

Authors:  Alison Rodway; J A Fleetwood; M F Laker; Sandra Knowles; P W Sanderson; M E Scott
Journal:  Br J Gen Pract       Date:  2002-10       Impact factor: 5.386

9.  Association of Acute Increases in Plasma Creatinine after Renin-Angiotensin Blockade with Subsequent Outcomes.

Authors:  Edouard L Fu; Marco Trevisan; Catherine M Clase; Marie Evans; Bengt Lindholm; Joris I Rotmans; Merel van Diepen; Friedo W Dekker; Juan-Jesus Carrero
Journal:  Clin J Am Soc Nephrol       Date:  2019-08-08       Impact factor: 8.237

Review 10.  Management of acute renal failure in the elderly patient: a clinician's guide.

Authors:  Ching M Cheung; Arvind Ponnusamy; John G Anderton
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.